Avalyn Pharma (NASDAQ:AVLN) Stock: Insider Fmr Llc Sells 175,000 Shares

Avalyn Pharma Inc. (NASDAQ:AVLN) insider Fmr Llc sold 175,000 shares of the company’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $29.07, for a total value of $5,087,250.00. Following the completion of the transaction, the insider owned 2,109,535 shares in the company, valued at $61,324,182.45. This represents a 7.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Fmr Llc also recently made the following trade(s):

• On Tuesday, November 10th, Fmr Llc sold 53,454 shares of Avalyn Pharma stock. The stock was sold at an average price of $30.21, for a total transaction of $1,614,845.34.

Avalyn Pharma Stock Performance

AVLN stock opened at $30.28 on Friday. The company has a quick ratio of 33.12, a current ratio of 33.12 and a debt-to-equity ratio of 0.04. The stock’s 50 day moving average is $28.66. Avalyn Pharma Inc. has a 52 week low of $22.24 and a 52 week high of $40.17.

Avalyn Pharma (NASDAQ:AVLN) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.03). On average, sell-side analysts forecast that Avalyn Pharma Inc. will post -3.86 earnings per share for the current year.

Hedge Funds Weigh In On Avalyn Pharma

Hedge funds have recently bought and sold shares of the business. Montanova Capital LLC acquired a new stake in shares of Avalyn Pharma in the second quarter worth about $82,402,000. Braidwell LP acquired a new position in shares of Avalyn Pharma during the 2nd quarter valued at about $26,382,000. State Street Corp raised its stake in shares of Avalyn Pharma by 73.7% in the 3rd quarter. State Street Corp now owns 554,004 shares of the company’s stock valued at $15,784,000 after acquiring an additional 235,009 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of Avalyn Pharma in the 2nd quarter valued at approximately $1,321,000. Finally, Profund Advisors LLC acquired a new stake in Avalyn Pharma in the 3rd quarter worth approximately $668,000.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on AVLN. Wall Street Zen upgraded Avalyn Pharma from a “sell” rating to a “hold” rating in a report on Saturday. Morgan Stanley upped their target price on Avalyn Pharma from $53.00 to $57.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Raymond James Financial began coverage on Avalyn Pharma in a report on Friday, October 2nd. They set an “outperform” rating and a $60.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Avalyn Pharma in a report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $60.00.

About Avalyn Pharma

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company’s pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn’s inhaled candidates are being studied as potential alternatives to oral treatment.